Sign in

CIK 0001652130

  • Large accelerated filer

Intellia Therapeutics, Inc.

Sign in to watch
Ticker
NTLA
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
364785571
Phone
+1 857-285-6200
Business address
400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
  1. 4 Grant or award EVP, Chief Scientific Officer acquired 37,966 shares (grant or award)
  2. 4 Open-market sale EVP, General Counsel sold 2,297 shares at $32.99 ($75,778)
  3. 4 Grant or award EVP, Chief Business Officer acquired 29,393 shares (grant or award)
  4. 4 Open-market sale EVP, Chief Technical Officer sold 605 shares at $32.99 ($19,959)
  5. 4 Grant or award President and CEO acquired 113,586 shares (grant or award)
  6. 4 Grant or award EVP, Chief Medical Officer acquired 38,701 shares (grant or award)
  7. 4 Grant or award EVP, Chief Financial Officer acquired 28,628 shares (grant or award)
  8. 4 Planned sale EVP, Chief Scientific Officer sold 2,275 shares at an average $28.87 ($65,682)
  9. 4 Open-market sale President and CEO sold 19,223 shares at $29.46 ($566,310)
  10. 4 Open-market sale EVP, Chief Medical Officer sold 5,843 shares at $29.46 ($172,135)
  11. 4 Open-market sale EVP, Chief Scientific Officer sold 5,532 shares at $29.46 ($162,973)
  12. 4 Open-market sale EVP, Chief Financial Officer sold 5,365 shares at $29.46 ($158,053)
  13. 4 Open-market sale EVP, Chief Business Officer sold 3,877 shares at $29.46 ($114,216)
  14. 4 Open-market sale EVP, General Counsel sold 3,805 shares at $29.46 ($112,095)
  15. 4 Open-market sale EVP, Chief Technical Officer sold 4,608 shares at an average $29.50 ($135,954)
  16. 4 Exercise or conversion EVP, Chief Scientific Officer acquired 3,500 shares (option exercise)
  17. 4 Exercise or conversion EVP, Chief Medical Officer acquired 3,187 shares (option exercise)
  18. 4 Exercise or conversion President and CEO acquired 7,848 shares (option exercise)
  19. 4 Exercise or conversion EVP, Chief Financial Officer acquired 3,062 shares (option exercise)
  20. 4 Planned sale Director sold 265 shares at $23.90 ($6,334)

Page 5 of 18 · 353 filings